Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects on cardiac repolarisation of
supratherapeutic doses of AZD3480 compared to placebo in healthy male volunteers, subgrouped
as extensive metabolisers and poor metabolisers according to CYP2D6 metabolic capacity, using
moxifloxacin as positive control.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination